Zusammenfassung
Die Bildung von Antikörpern gegen Faktor VIII (F VIII) stellt heute die schwerste Komplikation bei wiederholt substituierten Patienten mit Hämophilie A dar. Sie tritt bei etwa 15–33% der Patienten mit schwerer und mittelschwerer Hämophilie A auf [1–4].
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
Literatur
Schwarzinger I, Pabinger I, Korninger C, Haschke F, Kundi M, Niessner H, Leuchner K (1987) Incidence of inhibitors in patients with severe and moderate hemophilia A treated with factor VIII concentrates. A J Hematol 24:241 – 245
Schwartz RS, Abildgaard CF, Aledort LM, Arkin S, Bloom AL, Brackmann HH, Brettler DB, Fukui H, Hilgartner MW, Inwood MJ (1990) Human recombinant DNA-derived antihemophilic factor (F VIII) in the treatment of hemophilia A. N Engl J Med 323:1799 – 1805
Rasi V, Ikkala E (1990) Haemophiliacs with factor VIII inhibitors in Finland: prevalence, incidence and outcome. Br J Haematol 76:369 – 371
Ehrenforth S, Kreuz W, Scharrer I, Linde R, Funk M, Güngör T, Krackhardt B, Kornhuber B (1992) Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs. The Lancet 339:594 – 598
Kasper CK (1989) Treatment of factor VIII inhibitors. Progr Hemostas Thromb 9:57 – 86
Brackmann HH, Gormsen J (1977) Massive factor VIII in haemophiliac with factor VIII inhibitor, high responder. Lancet 2:993
Brackmann HH (1986) Induced immunotolerance in factor VIII inhibitor patients. Prog Clin Biol Res 150:181 – 185
Gomperts ED, Jordan S, Church JA, Sakai R, Lemire J (1984) Induction of tolerance to factor VIII in a child with a high-titer inhibitor: In vitro and in vivo observations. J Pediatr 104:70
Stenbjerg S, Ingerslev J, Zachariae E (1984) Factor VIII inhibitor treatment with high doses of factor VIII. Thromb Res 34:533 – 539
Scheibel E, Ingerslev J, Dalsgaard-Nielsen J, Stenbjerg S, Knudsen JB and the Danish Study Group (1987) Continuous high-dose factor VIII for the induction of immune tolerance in haemophilia A patients with high responder state: A description of eleven patients treated. Thromb Haemostas 58:1049
Sultan Y, White GC, Aronstam A, Bosser C, Brackmann HH, Brochier G, Gormsen J, Mariani G, Roberts HR, Scarabin Y, Scharrer I, Scheibel E (1986) Hemophilic patients with an inhibitor to factor VIII treated with high-dose factor VIII concentrate. Nouv Rev Fr Hematol 28:85–89
Sjamsoedin LJM, Heijnen L, Mauser-Bunschoten EP (1981) The effect of activated Prothrombin complex concentrate (FEIBA) on joint and muscle bleeding in patients with hemophilia A and antibodies to factor VIII. A randomised double blind clinical trial. N Engl J Med 305:717 – 721
Ewing NP, Sanders NL, Dietrich SL, Kasper CK (1988) Induction of immune tolerance to factor VIII in hemophiliacs with inhibitors. JAMA 259:65 – 68
Van Leeuwen EF, Mauser-Bundschoten EP, van Dijken PJ, Kok AJ, Sjamsoedin-Visser EJM, Sixma J (1986) Disappearance of factor VIII:C antibodies in patients with haemophilia A upon frequent administration of factor VIII in intermediate or low dose. Br J Haematol 64:291–297
Rizza CR, Matthews JM (1982) Effect of frequent factor VIII replacement on the level of factor VIII antibodies in haemophiliacs. Br J Haematol 52:13 – 24
Wensley RT, Burn AM, Reading OM (1985) Induction of tolerance to factor VIII in haemophilia A with inhibitors using low-doses of human factor VIII. (Abstr) Thromb Haemsotas 54:227
Langdell RD, Wagner RH, Brinkhous KM (1953) Effect of antihaemophilic factor on one-stage-clotting test: A presumptive test for haemophilia and a simple one-stage antihaemophilic factor assay procedure. J Lab Clin Med 41:637–645
Kasper CK, Aledort LM, Counts RB (1975) A more uniform measurement of factor VIII inhibitors. Thromb Diath Haemorrh 34:869
Ehrenforth S, Kreuz W, Scharrer I, Kornhuber B (1992b) Factor VIII inhibitors in haemophiliacs. The Lancet 340:253
Lusher JM (1987) Factor VIII inhibitors. Etiology, characterisation, natural history, and management. Ann N.Y. Acad Sci 509:89 – 102
Ewing NP (1990) Induction of immune tolerance with factor VIII concentrate in patients with hemophilia A and inhibitors. In: Kasper CK (ed) Recent Advances in Hemophilia Care, Alan R Liss Inc NY, p 59 – 68
Hedner U, Glazer S (1992) Management of hemophilia patients with inhibitors. In: Coagulation disorders I 6;5:1035 – 1046
Mariani G, Ghirardini A, Bellocco R (1994) Immune tolerance in Hemophilia — Principal results from the international registry. Thromb Haemost 72:155 – 158
Mauser-Bundschoten EP, Roosendaal G, Bruin M, van Dijken PJ (1990) Disappearance of factor VIII:C antibodies upon frequent administration of factor VIII. Folia-Haematol-Int-Mag-Klin-Morphol-Blutforsch 117(4): 533 – 537
Lusher JM, Shapiro SS, Palascak JE et al. (1980) Efficacy of prothrombin-complex concentrates in hemophiliacs with antibodies for factor VIII. A multicentral trial. N Eng J Med 303:421–425
Chiller JM, Habicht GS, Weigle WO (1971) Kinetic differences in unresponsiveness of thymus and bone marrow cells. Science 171:813 – 815
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1996 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Kreuz, W. et al. (1996). Immuntoleranztherapie bei Kindern mit Hemmkörperhämophilie. In: Scharrer, I., Schramm, W. (eds) 25. Hämophilie-Symposion Hamburg 1994. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-79648-7_10
Download citation
DOI: https://doi.org/10.1007/978-3-642-79648-7_10
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-59103-0
Online ISBN: 978-3-642-79648-7
eBook Packages: Springer Book Archive